129722-12-9 Aripiprazole AKSci J10066
 
 
Loading Please Wait...
  J10066    
Aripiprazole, >99% (HPLC)
 
7-[4-[4-(2,3-Dichlorophenyl)-1-piperazinyl]butoxy]-3,4-dihydro-2(1H)-quinolinone
IDENTITY
CAS Number:129722-12-9
MDL Number:MFCD00892072
MF:C23H27Cl2N3O2
MW:448.39
BRN:7951706
SPECIFICATIONS & PROPERTIES
Min. Purity Spec:>99% (HPLC)
Physical Form (at 20°C):Solid
Melting Point:134-140°C
Long-Term Storage:Store long-term at -20°C
DOT/IATA TRANSPORT INFORMATION
Not hazardous material

BIOLOGICAL INFO
Solubility:Insoluble in water, methanol, and hexane; soluble in acetic acid
Application(s):Human 5-HT1A receptor partial agonist

REVIEW
 Aripiprazole's antipsychotic activity is likely due to a combination of antagonism at D2 receptors in the mesolimbic pathway and 5HT2A receptors in the frontal cortex. Antagonism at D2 receptors relieves positive symptoms while antagonism at 5HT2A receptors relieves negative symptoms of schizophrenia.

REFERENCES
[1]Sachs G, Sanchez R, Marcus R, Stock E, McQuade R, Carson W, Abou-Gharbia N, Impellizzeri C, Kaplita S, Rollin L, Iwamoto T (July 2006). Aripiprazole in the treatment of acute manic or mixed episodes in patients with bipolar I disorder: a 3-week placebo-controlled study. J. Psychopharmacol. (Oxford) 20 (4): 536-46. doi:10.1177/0269881106059693. PMID 16401666.
[2] Vieta E, T'joen C, McQuade RD, Carson WH, Marcus RN, Sanchez R, Owen R, Nameche L (October 2008). Efficacy of adjunctive aripiprazole to either valproate or lithium in bipolar mania patients partially nonresponsive to valproate/lithium monotherapy: a placebo-controlled study. Am J Psychiatry 165 (10): 1316-25. doi:10.1176/appi.ajp.2008.07101560. PMID 18381903.
[3] Keck PE, Orsulak PJ, Cutler AJ, Sanchez R, Torbeyns A, Marcus RN, McQuade RD, Carson WH (January 2009). Aripiprazole monotherapy in the treatment of acute bipolar I mania: a randomized, double-blind, placebo- and lithium-controlled study. J Affect Disord 112 (1-3): 36-49. doi:10.1016/j.jad.2008.05.014. PMID 18835043.
[4] Mazza M, Squillacioti MR, Pecora RD, Janiri L, Bria P (December 2008). Beneficial acute antidepressant effects of aripiprazole as an adjunctive treatment or monotherapy in bipolar patients unresponsive to mood stabilizers: results from a 16-week open-label trial. Expert Opin Pharmacother 9 (18): 3145-9. doi:10.1517/14656560802504490. PMID 19040335.

GLOBALLY HARMONIZED SYSTEM (GHS)

Pictograms

Signal Word
Warning

Hazard Statements
H315; H319; H335

Precautionary Statements
P261; P264; P271; P280; P302+P352; P304+P340; P305+P351+P338; P312; P321; P332+P313; P337+P313; P362; P403+P233; P405; P501

Current as of May 9, 2024


Download SDS Request COA

All products are stocked and shipped from San Francisco Bay Area, California, USA.

⚠️
All products are for research and development use only, not for any other uses, and must be handled by technically-qualified persons.

These products are explicitly not intended to be used in foods and/or cosmetics and/or drugs (human and veterinary) and/or consumer products and/or biocides and/or pesticides of any kind unless explicitly stated otherwise.

Products are not sold to individuals. We do not ship to residential addresses. Consumer orders will be cancelled without notice.

New customers undergo an internal onboarding process. As part of this process, new customers may be asked for more information. Additional restrictions may apply.


CATEGORIES
 APIs and Bioactives > Antidepressants, Antipsychotics


PubChem